The OPARATIC trial has paved the way for two additional clinical trials — PARADIGM and PARADIGM - 2 —
testing olaparib in combination with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
Not exact matches
In this study, the researchers
tested the effects of
Olaparib on the tumors formed by human breast cancer cells injected into mice.
«This is the first study to
test the promise of a new kind of drug,
olaparib, for life - threatening prostate cancer no longer responding to best available treatment.
Based on these studies, the authors are designing a clinical trial to
test whether DNA repair inhibitors, such as
olaparib, are active against IDH1 - and IDH2 - mutant tumors.
One, known as
Olaparib, was identified and developed at KuDOS Pharmaceuticals and subsequently at AstraZeneca, and is being
tested at the ICR.